Why Moderna Stock Surged Today
Key Points
The National Institutes of Health (NIH) is reportedly planning to launch a cancer vaccine development program.
Moderna's experimental cancer therapy showed promising results in a recent clinical trial.
- 10 stocks we like better than Moderna ›
Shares of Moderna (NASDAQ:MRNA) jumped more than 14% on Friday, following reports of a major new cancer research initiative.
Image source: Getty Images.
Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
A new counteroffensive against cancer
The National Institutes of Health (NIH) plans to begin a campaign to fast-track cancer treatment research in December, according to a report by The New York Times. The program hopes to replicate the success of efforts to develop Covid-19 vaccines during the early stages of the pandemic.
The public-private partnership would bring together researchers and other resources from a range of healthcare companies and nonprofits to accelerate scientific discoveries. Initial research is expected to focus on pancreatic, liver, and colorectal cancer, as well as pediatric tumors.
Moderna is a leader in cancer vaccine research
The initiative comes at a time when advances in artificial intelligence (AI) and mRNA technology are making it possible for doctors to design treatments tailored to each patient's immune system.
On Aug. 19, Moderna and Merck (NYSE:MRK) announced that their co-developed investigational mRNA-based therapy, intismeran, when administered in combination with Merck's Keytruda, increased the time before cancer returned or spread in patients with high-risk melanoma.
These and other encouraging clinical trial results are prompting healthcare leaders to devote more resources to cancer research. That could help to accelerate Moderna's development timelines, potentially enabling the biotech to deliver new therapies to patients -- and profits to shareholders -- faster than previously expected.
Should you buy stock in Moderna right now?
Before you buy stock in Moderna, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Moderna wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $385,972!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,416,196!*
Now, it’s worth noting Stock Advisor’s total average return is 951% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of October 9, 2026.
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck and Moderna. The Motley Fool has a disclosure policy.
Recommended Articles
